EVIDENCE STARTS WITH US
Largest Body of Prospective Clinical Evidence in LITT
Our sole purpose at Monteris Medical is to create cutting-edge, minimally invasive technology that can forever change patients’ lives for the better. To that end, we continue to build upon our well-established and recognized leadership position in prospective evidence generation for LITT.
Landmark evidence from 787 patients demonstrates that greater extent of ablation with NeuroBlate significantly extends survival in patients with newly diagnosed and recurrent brain tumors.
PUBLISHED IN JAMA NEUROLOGY
The largest prospective cohort to date of LITT for drug‑resistant mesial temporal lobe epilepsy demonstrates that the NeuroBlate procedure was well tolerated and produced clinically meaningful seizure reduction and quality‑of‑life improvements.
Post-Market and Randomized Multicenter Clinical Trials
Monteris Medical is the established and recognized leader in LITT for the brain, setting the benchmark for precision, safety, and evidence-based outcomes. While LITT is increasingly adopted in neurosurgery, it is critical to recognize that only the NeuroBlate® System from Monteris is supported by an unparalleled foundation of peer-reviewed prospective evidence, demonstrating consistent performance across a wide range of brain pathologies, including primary and metastatic brain tumors, radiation necrosis, and drug-resistant epilepsy.
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate® System NCT02392078
- The first prospective multicenter laser ablation study in the brain.
- More than 1,000 patients enrolled across the U.S., received NeuroBlate, and were followed up to 5 years.
- Outcomes include safety, quality of life, health economics, procedural outcomes, seizure freedom, and survival. Enrollment completed.
Recurrent Brain Metastases after SRS Trial NCT05124912
- The first randomized, controlled, multicenter study investigating LITT with the NeuroBlate System as an early intervention for radiographically progressive brain metastases.
- Designed to deliver Level I evidence to guide the treatment algorithm for both the recurrent metastatic tumor and radiation necrosis populations following SRS.
- Currently enrolling.
Guidelines and Position Statements
LITT is included in the major neuro-oncology and neurosurgical societies’ guidelines, further supporting its use in oncology and drug-resistant epilepsy.
Investigator-Initiated Research Support
Monteris has an active investigator-initiated research program that allows us to partner with investigators on their LITT early-phase research. For more information, contact clinicalaffairs@monteris.com.
LEADING EXPERTS DISCUSS LITT EVIDENCE AND MORE
Hear from renowned physicians as they break down the latest published data, case reviews, and share their clinical experience. Visit our video channel to watch full discussions.
